Samir K Gupta, Frank A Post, José R Arribas, Joseph J Eron, David A Wohl, Amanda E Clarke, Paul E Sax, Hans-Jürgen Stellbrink, Stefan Esser, Anton L Pozniak, Daniel Podzamczer, Laura Waters, Chloe Orkin, Jürgen K Rockstroh, Tatiana Mudrikova, Eugenia Negredo, Richard A Elion, Susan Guo, Lijie Zhong, Christoph Carter, Hal Martin, Diana Brainard, Devi SenGupta, Moupali Das
OBJECTIVE: Compared with tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF) has been associated with improvement in markers of renal dysfunction in individual randomized trials; however, the comparative incidence of clinically significant renal events remains unclear. DESIGN: We used a pooled data approach to increase the person-years of drug exposure analysed, maximizing our ability to detect differences in clinically significant outcomes. METHODS: We pooled clinical renal safety data across 26 treatment-naive and antiretroviral switch studies to compare the incidence of proximal renal tubulopathy and discontinuation due to renal adverse events between participants taking TAF-containing regimens vs...
July 15, 2019: AIDS